MedChemExpress (MCE) 品牌
生产厂家厂商性质
国外所在地
Agro-like Library | MedChemExpress (MCE)
面议Premium Library | MedChemExpress (MCE)
面议Advanced Library | MedChemExpress (MCE)
面议HTS Compound Library | MedChemExpress (MCE)
面议MCE Fragment Library | MedChemExpress (MCE)
面议MCE Bioactive Compound Library | MedChemExpress (M
面议Targeted Diversity Library | MedChemExpress (MCE)
面议Novel Bioactive Compound Library | MedChemExpress
面议Camidanlumab | MedChemExpress
¥1200Cyclic-di-GMP diammonium | MedChemExpress
¥25006-Hydroxy Melatonin-d4 | MedChemExpress
¥7700β-Sitosterol-d7 (Mixture of Diastereomers) | MedCh
¥900MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1316214-52-4
MCE 国际站:Ricolinostat
产品活性:Ricolinostat (ACY-1215) 是一种有效,选择性的 HDAC6 抑制剂,IC50 为 5 nM。ACY-1215 也可抑制 HDAC1,HDAC2 和 HDAC3,IC50 分别为 58,48 和 51 nM。
研究领域:Cell Cycle/DNA Damage | Epigenetics | Apoptosis
作用靶点:HDAC | Apoptosis
In Vitro: Ricolinostat (ACY-1215) has slight activity against HDAC8 (IC50=0.1 μM), and has minimal activity (IC50>1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2. The effect of Ricolinostat (ACY-1215) on multiple myeloma (MM) cell viability is determined with MTT assays using MM cell lines. Exposure of MM cell lines for 48 hours results in dose-dependent decreased viability, with IC50 values ranging from 2-8μM. Ricolinostat (ACY-1215) demonstrates significant activity in the MM PS-341-resistant cell line (ANBL-6.BR), demonstrating the ability of Ricolinostat (ACY-1215) to overcome PS-341 resistance.
In Vivo: Mice treated with Ricolinostat (ACY-1215), PS-341, or Ricolinostat plus PS-341 show a significant delay in tumor growth (P=0.01, P=0.006, and P<0.0001, respectively). Combined treatment with Ricolinostat and PS-341 shows significant suppression of tumor growth and significantly prolonged overall survival (OS) compare with the control group (17 days in the control vs 40 days in the combination-treated group, P<0.0001) and the Ricolinostat (ACY-1215)-treated group (22 days in the PS-341 group vs 40 days in the combination-treated group, P<0.0001). Weight loss in the combination-treated group is between 4% and 12% compare with the same-day control group values during treatment, with complete recovery after the last injection. As is observed in the plasmacytoma model, a significant therapeutic advantage is found by combining Ricolinostat with PS-341 compare with either agent alone.
相关产品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Human Metabolite Library | Anti-Pulmonary Fibrosis Compound Library | Osteogenesis Compound Library | Heterocyclic Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cell Death Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Trichostatin A
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds